• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增殖性糖尿病视网膜病变初次全视网膜光凝时的眼部表现可预测未来是否需要行玻璃体切割术。

Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy.

作者信息

Parikh Ravi, Shah Rohan J, VanHouten Jacob P, Cherney Edward F

机构信息

Departments of *Ophthalmology and Visual Sciences, †Biomedical Informatics, and ‡Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.

出版信息

Retina. 2014 Oct;34(10):1997-2002. doi: 10.1097/IAE.0000000000000192.

DOI:10.1097/IAE.0000000000000192
PMID:24936944
Abstract

PURPOSE

To determine the 1-year and 2-year likelihood of vitrectomy in diabetic patients undergoing initial pan retinal photocoagulation (PRP).

METHODS

Diabetic eyes receiving initial PRP for proliferative diabetic retinopathy (PDR) were analyzed to determine their risk for vitrectomy based on clinical findings.

RESULTS

In total, 374 eyes of 272 patients were analyzed. The percentage of eyes undergoing vitrectomy 1 year and 2 years following initial PRP was 19.1% and 26.2%, respectively. Of the eyes in Group 1 (PDR alone), Group 2 (PDR and vitreous hemorrhage), and Group 3 (PDR and iris neovascularization, vitreous hemorrhage with traction or fibrosis, or fibrosis alone), the percentage receiving pars plana vitrectomy at 1 year and 2 years was 9.73% (18/185) and 15.7% (29/185), 26.9% (43/160) and 34.4% (55/160), and 37.9% (11/29) and 48.3% (14/29), respectively. Eyes in Group 2 had 2.78 times greater likelihood (P < 0.0001) and eyes in Group 3 had 3.54 times higher likelihood (P < 0.0001) of requiring pars plana vitrectomy within 2 years than those with PDR alone.

CONCLUSION

Eyes receiving PRP for PDR with associated hemorrhage or traction were more likely to undergo pars plana vitrectomy within 1 year and 2 years following initial PRP compared with eyes with only PDR, providing important prognostic information for PRP-naive patients.

摘要

目的

确定接受初次全视网膜光凝(PRP)的糖尿病患者在1年和2年内进行玻璃体切除术的可能性。

方法

对因增殖性糖尿病视网膜病变(PDR)接受初次PRP的糖尿病眼进行分析,根据临床发现确定其玻璃体切除术风险。

结果

共分析了272例患者的374只眼。初次PRP后1年和2年接受玻璃体切除术的眼的百分比分别为19.1%和26.2%。在第1组(仅PDR)、第2组(PDR和玻璃体出血)和第3组(PDR和虹膜新生血管、伴有牵拉或纤维化的玻璃体出血或仅纤维化)的眼中,1年和2年接受玻璃体切割术的百分比分别为9.73%(18/185)和15.7%(29/185)、26.9%(43/160)和34.4%(55/160)、37.9%(11/29)和48.3%(14/29)。与仅患有PDR的眼相比,第2组的眼在2年内需要进行玻璃体切割术的可能性高2.78倍(P<0.0001),第3组的眼在2年内需要进行玻璃体切割术的可能性高3.54倍(P<0.0001)。

结论

与仅患有PDR的眼相比,因PDR伴有出血或牵拉而接受PRP的眼在初次PRP后的1年和2年内更有可能接受玻璃体切割术,这为未接受过PRP的患者提供了重要的预后信息。

相似文献

1
Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy.增殖性糖尿病视网膜病变初次全视网膜光凝时的眼部表现可预测未来是否需要行玻璃体切割术。
Retina. 2014 Oct;34(10):1997-2002. doi: 10.1097/IAE.0000000000000192.
2
Endodiathermy plus photocoagulation as treatment of sclerotomy site vascularization secondary to pars plana vitrectomy for proliferative diabetic retinopathy.内切开联合光凝治疗增殖性糖尿病视网膜病变行玻璃体切割术后巩膜切口血管化。
Retina. 2012 Jul;32(7):1310-5. doi: 10.1097/IAE.0b013e318236e7ef.
3
Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.增殖性糖尿病视网膜病变患者进展为玻璃体切割术的情况。
JAMA Ophthalmol. 2024 Jul 1;142(7):662-668. doi: 10.1001/jamaophthalmol.2024.1844.
4
Clinical Characteristics of Proliferative Diabetic Retinopathy and Outcome of Pars Plana Vitrectomy in Proliferative Diabetic Retinopathy.增生型糖尿病视网膜病变的临床特征及增生型糖尿病视网膜病变行玻璃体切除术的疗效。
J Nepal Health Res Counc. 2024 Jun 22;22(1):157-162. doi: 10.33314/jnhrc.v22i01.4958.
5
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.全视网膜光凝或雷珠单抗治疗的眼中与增殖性糖尿病视网膜病变恶化相关的因素
Ophthalmology. 2017 Apr;124(4):431-439. doi: 10.1016/j.ophtha.2016.12.005. Epub 2017 Feb 1.
6
Reasons for and management of postvitrectomy vitreous hemorrhage in proliferative diabetic retinopathy.增生型糖尿病视网膜病变玻璃体切割术后玻璃体积血的原因及处理。
Curr Eye Res. 2010 Apr;35(4):308-13. doi: 10.3109/02713680903572491.
7
Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.糖尿病视网膜病变早期治疗研究中的玻璃体切除术。ETDRS报告第17号。糖尿病视网膜病变早期治疗研究研究组。
Ophthalmology. 1992 Sep;99(9):1351-7. doi: 10.1016/s0161-6420(92)31779-8.
8
Predictors of visual outcome after pars plana vitrectomy secondary to proliferative diabetic retinopathy.增生型糖尿病视网膜病变行玻璃体切除术患者的视力预后预测因素。
Rom J Ophthalmol. 2023 Jul-Sep;67(3):283-288. doi: 10.22336/rjo.2023.46.
9
Risk Factors of Neovascular Glaucoma After 25-gauge Vitrectomy for Proliferative Diabetic Retinopathy with Vitreous Hemorrhage: A Retrospective Multicenter Study.增生型糖尿病视网膜病变伴玻璃体积血 25G 玻璃体切割术后新生血管性青光眼的危险因素:一项回顾性多中心研究。
Sci Rep. 2019 Oct 16;9(1):14858. doi: 10.1038/s41598-019-51411-6.
10
Vitrectomy for proliferative diabetic retinopathy with asteroid hyalosis.玻璃体切割术治疗增殖性糖尿病视网膜病变合并星状玻璃体病变。
Retina. 1998;18(5):410-4. doi: 10.1097/00006982-199805000-00004.

引用本文的文献

1
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis.抗血管内皮生长因子药物与激光光凝术治疗糖尿病视网膜病变的比较:系统评价与经济分析
Health Technol Assess. 2025 May 7:1-16. doi: 10.3310/KRWP1264.
2
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗增殖性糖尿病视网膜病变的比较:一项系统评价和个体参与者数据荟萃分析
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
3
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.
抗血管内皮生长因子药物与激光光凝术治疗糖尿病性视网膜病变的比较:一项系统评价和荟萃分析。
Health Technol Assess. 2024 Dec 11:1-71. doi: 10.3310/PCGV5709.
4
Association of Anemia and Diabetic Retinopathy Among Patients With Type 2 Diabetes Mellitus: Retrospective Cross-Sectional Study.2型糖尿病患者贫血与糖尿病视网膜病变的关联:回顾性横断面研究
Cureus. 2024 Aug 28;16(8):e67995. doi: 10.7759/cureus.67995. eCollection 2024 Aug.
5
Outcomes of Pars Plana Vitrectomy with Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Without Retinal Detachment: A Seven-Year Retrospective Study.不伴有视网膜脱离的增生性糖尿病视网膜病变行玻璃体切割联合全视网膜光凝术的疗效:一项七年回顾性研究
Clin Ophthalmol. 2023 Feb 1;17:471-478. doi: 10.2147/OPTH.S400474. eCollection 2023.
6
Safety and effectiveness of pre-emptive diabetic vitrectomy in patients with severe, non-fibrotic retinal neovascularisation despite panretinal photocoagulation.尽管进行了全视网膜光凝,但对于严重非纤维性视网膜新生血管化的糖尿病患者,预防性糖尿病玻璃体切除术的安全性和有效性。
Eye (Lond). 2023 Jun;37(8):1553-1557. doi: 10.1038/s41433-022-02167-3. Epub 2022 Jul 21.
7
Retinal fibrosis in diabetic retinopathy.糖尿病视网膜病变中的视网膜纤维化
Exp Eye Res. 2016 Jan;142:71-5. doi: 10.1016/j.exer.2015.04.004.